Dexcom’s Glucose Monitors Give Dangerous False Readings, Lawsuit Alleges

Case Overview: A class action lawsuit accuses Dexcom of selling G6 and G7 glucose monitors with unapproved material changes that caused false readings and potential health risks.

Consumers Affected: Individuals across the U.S. who bought or used Dexcom G6 or G7 devices manufactured with altered sensor materials.

Court: U.S. District Court for the Southern District of California

Dexcom, the California medical device company, is facing a lawsuit claiming its G6 and G7 glucose monitors give dangerously inaccurate blood sugar readings.

The devices are designed to track glucose levels continuously and alert users to dangerous highs and lows. According to the complaint, they often fail to do even that.

The suit says Dexcom misled consumers by promoting the monitors as highly accurate and FDA-cleared while secretly changing the sensors’ materials in ways that weakened performance. 

Those changes, the plaintiffs claim, were made without regulatory approval and caused the devices to produce false readings that could endanger users who depend on them for daily care.

Patients Say Dexcom Misled Buyers About Device Accuracy

California residents Caroline Levens and Gisell Cordova Regis filed the lawsuit after their monitors repeatedly gave incorrect readings compared to manual blood sugar checks. Both say they relied on Dexcom’s marketing promises of “industry-leading accuracy” and “scientifically proven” technology.

Levens began using Dexcom products in 2018, while Cordova Regis purchased the G7 model in 2024. Each says her insurance helped pay for the devices, which cost hundreds of dollars but failed to perform as advertised.

FDA Found Unauthorized Material Changes in G6 and G7 Sensors

A March 2025 FDA warning letter cited in the lawsuit found that Dexcom had changed a key material in its G6 and G7 sensors without approval. The altered sensors showed “considerably greater variability” in testing, which made them less dependable for people managing diabetes.

The FDA said the modified products were “adulterated” and “misbranded” and that Dexcom should have submitted them for new review before release. The agency warned that the unapproved changes could increase the risk of harm for patients relying on the readings to make medical decisions.

Medical Device Defect Lawsuits Continue to Grow Nationwide

The case against Dexcom joins a series of recent lawsuits over defective medical and consumer health products.

Pharmaceutical company Glenmark faces litigation over recalled potassium chloride capsules linked to life-threatening risks, while Scope Health was sued for selling unapproved eye drops. 

Bard PowerPort devices are under investigation after hundreds of reports of injury, and GlaxoSmithKline, Pfizer, and Sanofi recently settled tens of thousands of cancer claims tied to Zantac.

Levens and Cordova Regis are seeking to represent all U.S. consumers who purchased Dexcom G6 or G7 devices made with the unapproved materials. Their lawsuit accuses Dexcom of breaching warranties, violating consumer protection laws, and misrepresenting the reliability of its products. 

They are asking for damages, refunds, and an injunction to stop Dexcom from selling monitors that, in their words, “failed to do the one thing they were built to do.”

Case Details

• Lawsuit: Levens, et al. v. Dexcom, Inc., et al.
• Case Number: 3:25-cv-02565-BEN-BLM
• Court: U.S. District Court for the Southern District of California

Plaintiffs' Attorneys

• Behram V. Parekh (Wisner Baum, LLP)

Do you use a Dexcom G6 or G7 monitor? Have you experienced false readings or device issues? Share your story in the comments below.